{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T16:57:03Z","timestamp":1785603423949,"version":"3.56.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:00:00Z","timestamp":1759968000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:00:00Z","timestamp":1759968000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Medizinische Hochschule Hannover (MHH)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neural Transm"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Polyneuropathy (PNP) is increasingly recognized as a comorbidity in Parkinson\u2019s disease (PD) but its prevalence, clinical features and impact in atypical Parkinsonian syndromes (APS) remain unclear. Understanding PNP in Parkinsonism is crucial for improving patients\u2019 mobility, slowing the disability progression and reducing disease burden. This study aims to characterize prevalence, etiology, and clinical relevance of PNP in PD and APS. Consecutive admissions of 104 PD, 52 progressive supranuclear palsy (PSP), and 27 multiple system atrophy (MSA) patients to the Department of Neurology at Hannover Medical School were analyzed. Assessments included Hoehn and Yahr stage, MDS-UPDRS III, electroneurography, PNP related conditions (e.g., diabetes mellitus, vitamin deficiencies), and PD drugs including levodopa equivalence dose (LED). PNP was highly prevalent across all three groups with a prevalence ranging from 37.0% and 47.1%. PD and PSP patients with PNP were older and predominantly male (p\u2009&lt;\u20090.05). They also showed more advanced Hoehn and Yahr stages and higher MDS-UPDRS-III scores (p\u2009&lt;\u20090.05). Sensorimotor axonal, length\u2010dependent peripheral neuropathy was the most frequent presentation. We found no association between PNP and PD medications, and classic risk factors for PNP, such as diabetes mellitus, vitamin B12 deficiency, or chronic alcohol abuse, did not differ significantly between patients with and without PNP. Screening for PNP among patients with Parkinsonism, particularly among older males, is critical to optimize mobility. Further studies to identify the cause of the high prevalence of PNP among this population are needed.<\/jats:p>","DOI":"10.1007\/s00702-025-03032-9","type":"journal-article","created":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T08:00:31Z","timestamp":1759996831000},"page":"1329-1338","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Polyneuropathy in Parkinson\u2019s disease and atypical Parkinsonian syndromes: clinical impact and risk factors"],"prefix":"10.1007","volume":"133","author":[{"given":"Am\u00e9lie L.","family":"Conring","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3508-7359","authenticated-orcid":false,"given":"Lan","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Wegner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"K\u00f6rner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Hegelmaier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"H\u00f6llerhage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Klietz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,9]]},"reference":[{"issue":"6","key":"3032_CR1","first-page":"83","volume":"115","author":"C Sommer","year":"2018","unstructured":"Sommer C, Geber C, Young P, Forst R, Birklein F, Schoser B (2018) Polyneuropathies. Dtsch Arztebl Int 115(6):83","journal-title":"Dtsch Arztebl Int"},{"issue":"6","key":"3032_CR2","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1001\/jamaneurol.2022.0565","volume":"79","author":"MA Elafros","year":"2022","unstructured":"Elafros MA, Kvalsund MP, Callaghan BC (2022) The global burden of polyneuropathy\u2014in need of an accurate assessment. JAMA Neurol 79(6):537\u2013538","journal-title":"JAMA Neurol"},{"issue":"1","key":"3032_CR3","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1002\/ana.22021","volume":"68","author":"C Toth","year":"2010","unstructured":"Toth C, Breithaupt K, Ge S et al (2010) Levodopa, methylmalonic acid, and neuropathy in idiopathic Parkinson disease. Ann Neurol 68(1):28\u201336","journal-title":"Ann Neurol"},{"issue":"8","key":"3032_CR4","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1002\/mds.27025","volume":"32","author":"A Merola","year":"2017","unstructured":"Merola A, Rosso M, Romagnolo A et al (2017) Peripheral neuropathy as marker of severe Parkinson\u2019s disease phenotype. Mov Disorder 32(8):1256\u20131258","journal-title":"Mov Disorder"},{"issue":"1","key":"3032_CR5","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1093\/brain\/awac026","volume":"146","author":"MF Corr\u00e0","year":"2023","unstructured":"Corr\u00e0 MF, Vila-Ch\u00e3 N, Sardoeira A et al (2023) Peripheral neuropathy in Parkinson\u2019s disease: prevalence and functional impact on gait and balance. Brain 146(1):225\u2013236","journal-title":"Brain"},{"issue":"1","key":"3032_CR6","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41572-021-00280-3","volume":"7","author":"D Aarsland","year":"2021","unstructured":"Aarsland D, Batzu L, Halliday GM, Geurtsen GJ, Ballard C, Ray Chaudhuri K, Weintraub D (2021) Parkinson disease-associated cognitive impairment. Nat Rev Dis Primers 7(1):47","journal-title":"Nat Rev Dis Primers"},{"key":"3032_CR7","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/B978-0-444-64012-3.00009-5","volume":"165","author":"G Fabbrini","year":"2019","unstructured":"Fabbrini G, Fabbrini A, Suppa A (2019) Progressive supranuclear palsy, multiple system atrophy and corticobasal degeneration. Handb Clin Neurol 165:155\u2013177","journal-title":"Handb Clin Neurol"},{"issue":"5","key":"3032_CR8","doi-asserted-by":"publisher","first-page":"2639","DOI":"10.1007\/s00415-024-12207-5","volume":"271","author":"L Ye","year":"2024","unstructured":"Ye L, Greten S, Wegner F, Doll-Lee J et al (2024) The comorbidity profiles and medication issues of patients with multiple system atrophy: a systematic cross-sectional analysis. J Neurol 271(5):2639\u20132648","journal-title":"J Neurol"},{"issue":"2","key":"3032_CR9","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1007\/s00415-023-12006-4","volume":"271","author":"S Greten","year":"2024","unstructured":"Greten S, Wegner F, Jensen I et al (2024) The comorbidity and co-medication profile of patients with progressive supranuclear palsy. J Neurol 271(2):782\u2013793","journal-title":"J Neurol"},{"key":"3032_CR10","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s40266-019-00654-z","volume":"36","author":"M Klietz","year":"2019","unstructured":"Klietz M, Greten S, Wegner F, H\u00f6glinger GU (2019) Safety and tolerability of pharmacotherapies for Parkinson\u2019s disease in geriatric patients. Drugs Aging 36:511\u2013530","journal-title":"Drugs Aging"},{"issue":"7","key":"3032_CR11","doi-asserted-by":"publisher","first-page":"879","DOI":"10.3390\/brainsci11070879","volume":"11","author":"R Rohmann","year":"2021","unstructured":"Rohmann R, K\u00fchn E, Scherbaum R et al (2021) Prevalence and characteristics of polyneuropathy in atypical Parkinsonian syndromes: an explorative study. Brain Sci 11(7):879","journal-title":"Brain Sci"},{"key":"3032_CR12","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s10654-015-0094-6","volume":"31","author":"R Hanewinckel","year":"2016","unstructured":"Hanewinckel R, van Oijen M, Ikram MA, van Doorn PA (2016a) The epidemiology and risk factors of chronic polyneuropathy. Eur J Epidemiol 31:5\u201320","journal-title":"Eur J Epidemiol"},{"key":"3032_CR13","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-025-02882-7","author":"O Stockmann","year":"2025","unstructured":"Stockmann O, Ye L, Greten S, Chemodanow D, Wegner F, Klietz M (2025) Impact of diabetes mellitus type two on incidence and progression of Parkinson\u2019s disease: a systematic review of longitudinal patient cohorts. J Neural Transm. https:\/\/doi.org\/10.1007\/s00702-025-02882-7","journal-title":"J Neural Transm"},{"issue":"2","key":"3032_CR14","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1002\/mdc3.12688","volume":"6","author":"A Romagnolo","year":"2019","unstructured":"Romagnolo A, Merola A, Artusi CA, Rizzone MG, Zibetti M, Lopiano L (2019) Levodopa-induced neuropathy: a systematic review. Mov Disord Clin Pract 6(2):96\u2013103","journal-title":"Mov Disord Clin Pract"},{"key":"3032_CR15","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.parkreldis.2016.04.016","volume":"27","author":"G Cossu","year":"2016","unstructured":"Cossu G, Ceravolo R, Zibetti M et al (2016) Levodopa and neuropathy risk in patients with Parkinson disease: effect of COMT inhibition. Parkinsonism Relat Disord 27:81\u201384","journal-title":"Parkinsonism Relat Disord"},{"issue":"7","key":"3032_CR16","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1517\/17425255.2011.575779","volume":"7","author":"T M\u00fcller","year":"2011","unstructured":"M\u00fcller T (2011) Motor complications, levodopa metabolism and progression of Parkinson\u2019s disease. Expert Opin Drug Metab Toxicol 7(7):847\u2013855","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"12","key":"3032_CR17","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/mds.26424","volume":"30","author":"RB Postuma","year":"2015","unstructured":"Postuma RB, Berg D, Stern M et al (2015) MDS clinical diagnostic criteria for Parkinson\u2019s disease. Mov Disord 30(12):1591\u20131601","journal-title":"Mov Disord"},{"issue":"6","key":"3032_CR18","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1002\/mds.26987","volume":"32","author":"GU H\u00f6glinger","year":"2017","unstructured":"H\u00f6glinger GU, Respondek G, Stamelou M et al (2017) Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria. Mov Disord 32(6):853\u2013864","journal-title":"Mov Disord"},{"issue":"9","key":"3032_CR19","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1212\/01.wnl.0000324625.00404.15","volume":"71","author":"S Gilman","year":"2008","unstructured":"Gilman S, Wenning GK, Low PA et al (2008) Second consensus statement on the diagnosis of multiple system atrophy. Neurology 71(9):670\u2013676","journal-title":"Neurology"},{"key":"3032_CR20","unstructured":"Heu\u00df D. et al., Diagnostik bei Polyneuropathien, S1-Leitlinie, (2024), in: Deutsche Gesellschaft f\u00fcr Neurologie (Hrsg.), Leitlinien f\u00fcr Diagnostik und Therapie in der Neurologie. Online: www.dgn.org\/leitlinien (abgerufen am 27.03.2025)"},{"issue":"5","key":"3032_CR21","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1212\/WNL.17.5.427","volume":"17","author":"MM Hoehn","year":"1967","unstructured":"Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression, and mortality. Neurology 17(5):427\u2013427","journal-title":"Neurology"},{"issue":"15","key":"3032_CR22","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1002\/mds.22340","volume":"23","author":"CG Goetz","year":"2008","unstructured":"Goetz CG, Tilley BC, Shaftman SR et al (2008) Movement disorder society-sponsored revision of the Unified Parkinson\u2019s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 23(15):2129\u20132170","journal-title":"Mov Disord"},{"issue":"4","key":"3032_CR23","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/j.1532-5415.2005.53221.x","volume":"53","author":"ZS Nasreddine","year":"2005","unstructured":"Nasreddine ZS, Phillips NA, B\u00e9dirian V et al (2005) The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 53(4):695\u2013699","journal-title":"J Am Geriatr Soc"},{"issue":"1","key":"3032_CR24","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1002\/mds.27862","volume":"35","author":"KR Chaudhuri","year":"2020","unstructured":"Chaudhuri KR, Schrag A, Weintraub D, Rizos A, Rodriguez-Blazquez C, Mamikonyan E, Martinez-Martin P (2020) The movement disorder society nonmotor rating scale: initial validation study. Mov Disord 35(1):116\u2013133","journal-title":"Mov Disord"},{"issue":"11","key":"3032_CR25","doi-asserted-by":"publisher","first-page":"7071","DOI":"10.1007\/s00415-024-12632-6","volume":"271","author":"M H\u00f6llerhage","year":"2024","unstructured":"H\u00f6llerhage M, Becktepe J, Classen J et al (2024) Pharmacotherapy of motor symptoms in early and mid-stage Parkinson\u2019s disease: guideline \u201cParkinson\u2019s disease\u201d of the German Society of Neurology. J Neurol 271(11):7071\u20137101","journal-title":"J Neurol"},{"issue":"8","key":"3032_CR26","doi-asserted-by":"publisher","first-page":"2908","DOI":"10.1007\/s00415-021-10459-z","volume":"268","author":"T Seeliger","year":"2021","unstructured":"Seeliger T, Gingele S, B\u00f6nig L et al (2021) CIDP associated with Sj\u00f6gren\u2019s syndrome. J Neurol 268(8):2908\u20132912","journal-title":"J Neurol"},{"key":"3032_CR27","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.3389\/fimmu.2019.01600","volume":"10","author":"T Seeliger","year":"2019","unstructured":"Seeliger T, Prenzler NK, Gingele S et al (2019) Neuro-Sj\u00f6gren: peripheral neuropathy with limb weakness in Sj\u00f6gren\u2019s syndrome. Front Immunol 10:1600","journal-title":"Front Immunol"},{"issue":"9","key":"3032_CR28","doi-asserted-by":"publisher","first-page":"6136","DOI":"10.1007\/s00415-024-12579-8","volume":"271","author":"EH Kwon","year":"2024","unstructured":"Kwon EH, Bieber A, Sch\u00fclken P et al (2024) Longitudinal evaluation of polyneuropathy in Parkinson\u2019s disease. J Neurol 271(9):6136\u20136146","journal-title":"J Neurol"},{"key":"3032_CR29","volume-title":"EMG NLG: Elektromyografie\u2014Nervenleitungsuntersuchungen","author":"C Bischoff","year":"2018","unstructured":"Bischoff C, Dengler R (2018) EMG NLG: Elektromyografie\u2014Nervenleitungsuntersuchungen, 4th edn. Thieme Verlag, Stuttgart","edition":"4"},{"issue":"17","key":"3032_CR30","first-page":"306","volume":"107","author":"K Jahn","year":"2010","unstructured":"Jahn K, Zwergal A, Schniepp R (2010) Gait disturbances in old age: classification, diagnosis, and treatment from a neurological perspective. Dtsch Arztebl Int 107(17):306","journal-title":"Dtsch Arztebl Int"},{"issue":"18","key":"3032_CR31","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1212\/WNL.0000000000003293","volume":"87","author":"R Hanewinckel","year":"2016","unstructured":"Hanewinckel R, Drenthen J, van Oijen M, Hofman A, van Doorn PA, Ikram MA (2016b) Prevalence of polyneuropathy in the general middle-aged and elderly population. Neurology 87(18):1892\u20131898","journal-title":"Neurology"},{"key":"3032_CR32","unstructured":"Gierthm\u00fchlen J, Attal N, Baskozos G, et al. (2022) What is associated with painful polyneuropathy? A cross-sectional analysis of symptoms and signs in patients with painful and painless polyneuropathy. PAIN, 10\u20131097."},{"issue":"3","key":"3032_CR33","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1212\/WNL.0000000000001160","volume":"84","author":"NA Visser","year":"2015","unstructured":"Visser NA, Notermans NC, Linssen RS, van den Berg LH, Vrancken AF (2015) Incidence of polyneuropathy in Utrecht, The Netherlands. Neurology 84(3):259\u2013264","journal-title":"Neurology"},{"issue":"01","key":"3032_CR34","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1055\/a-2252-1780","volume":"55","author":"V Kleinveld","year":"2024","unstructured":"Kleinveld V, Eggers C, L\u00f6scher W, Sick CC (2024) Einfluss des Patientenalters auf Parameter der Elektroneurographie. Klin Neurophysiol 55(01):8\u201315","journal-title":"Klin Neurophysiol"},{"issue":"4","key":"3032_CR35","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1176\/jnp.2010.22.4.451.e16","volume":"22","author":"S Sahin","year":"2010","unstructured":"Sahin S, Cinar N, Sezgin G, Ayalp S, Karsidag S (2010) Acute motor axonal neuropathy: a severe complication of alcohol abuse. J Neuropsychiatry Clin Neurosci 22(4):451-e16","journal-title":"J Neuropsychiatry Clin Neurosci"},{"issue":"1","key":"3032_CR36","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/0022-510X(84)90147-3","volume":"66","author":"PA McCombe","year":"1984","unstructured":"McCombe PA, McLeod JG (1984) The peripheral neuropathy of vitamin B12 deficiency. J Neurol Sci 66(1):117\u2013126","journal-title":"J Neurol Sci"},{"issue":"5","key":"3032_CR37","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.698","volume":"7","author":"S Loens","year":"2017","unstructured":"Loens S, Chorbadzhieva E, Kleimann A, Dressler D, Schrader C (2017) Effects of levodopa\/carbidopa intestinal gel versus oral levodopa\/carbidopa on B vitamin levels and neuropathy. Brain Behav 7(5):e00698","journal-title":"Brain Behav"},{"issue":"10","key":"3032_CR38","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1038\/s41593-018-0238-6","volume":"21","author":"M Jucker","year":"2018","unstructured":"Jucker M, Walker LC (2018) Propagation and spread of pathogenic protein assemblies in neurodegenerative diseases. Nat Neurosci 21(10):1341\u20131349","journal-title":"Nat Neurosci"},{"issue":"7","key":"3032_CR39","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/j.amjmed.2019.03.001","volume":"132","author":"MT Hayes","year":"2019","unstructured":"Hayes MT (2019) Parkinson\u2019s disease and parkinsonism. Am J Med 132(7):802\u2013807","journal-title":"Am J Med"},{"issue":"7","key":"3032_CR40","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/S1474-4422(17)30157-6","volume":"16","author":"AL Boxer","year":"2017","unstructured":"Boxer AL, Yu JT, Golbe LI, Litvan I, Lang AE, H\u00f6glinger GU (2017) Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches. Lancet Neurol 16(7):552\u2013563","journal-title":"Lancet Neurol"},{"issue":"1","key":"3032_CR41","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41572-022-00382-6","volume":"8","author":"W Poewe","year":"2022","unstructured":"Poewe W, Stankovic I, Halliday G et al (2022) Multiple system atrophy. Nat Rev Dis Primers 8(1):56","journal-title":"Nat Rev Dis Primers"},{"issue":"3","key":"3032_CR42","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1002\/acn3.52282","volume":"12","author":"A Emmi","year":"2024","unstructured":"Emmi A, Mammana A, Sandre M et al (2024) Alpha-synuclein RT-QuIC assay in gastroduodenal and skin biopsies of Parkinson disease patients. Ann Clin Transl Neurol 12(3):637\u2013642","journal-title":"Ann Clin Transl Neurol"},{"issue":"15","key":"3032_CR43","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1001\/jama.2024.0792","volume":"331","author":"CH Gibbons","year":"2024","unstructured":"Gibbons CH, Levine T, Adler C et al (2024) Skin biopsy detection of phosphorylated \u03b1-synuclein in patients with synucleinopathies. JAMA 331(15):1298\u20131306","journal-title":"JAMA"},{"issue":"15","key":"3032_CR44","doi-asserted-by":"publisher","first-page":"e1529","DOI":"10.1212\/WNL.0000000000206772","volume":"100","author":"C Gibbons","year":"2023","unstructured":"Gibbons C, Wang N, Rajan S, Kern D, Palma JA, Kaufmann H, Freeman R (2023) Cutaneous \u03b1-synuclein signatures in patients with multiple system atrophy and Parkinson disease. Neurology 100(15):e1529\u2013e1539","journal-title":"Neurology"}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-025-03032-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00702-025-03032-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-025-03032-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T16:06:41Z","timestamp":1785600401000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00702-025-03032-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,9]]},"references-count":44,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["3032"],"URL":"https:\/\/doi.org\/10.1007\/s00702-025-03032-9","relation":{},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"value":"0300-9564","type":"print"},{"value":"1435-1463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,9]]},"assertion":[{"value":"30 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that there are no conflicts of interest relevant to this work. Martin Klietz serves as a consultant for Abbvie; received honoraria for scientific presentations from Abbvie, Ever and Bial. MK was funded by the German Parkinson\u2019s disease association, MHH plus foundation (Hannover, Germany) and Petermax M\u00fcller Foundation (Hannover, Germany).","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}